Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430261 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
A Phase 2 study of Lung Cancer and Adenocarcinoma, sponsored by Swedish Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00430261: Completed Phase 2 study of Lung Cancer and Adenocarcinoma, sponsored by Swedish Medical Center.
NCT00430261 is a Phase 2 study of Lung Cancer and Adenocarcinoma that has completed, run by Swedish Medical Center. The registered enrollment target is 20 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430261, a Phase 2 study of Lung Cancer and Adenocarcinoma, has completed, sponsored by Swedish Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.
Conditions Studied
Interventions
- DRUG sunitinib
Study Locations (1)
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-01 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
What the finished NCT00430261 record still lists
NCT00430261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which sunitinib is the first listed.
NCT00430261 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00430261 about?
NCT00430261 is a clinical study titled "Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma". This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime) the cancer can be any type of adenocarcinoma.
What is the current status of trial NCT00430261?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-01. Estimated completion is 2010-10.
What conditions does trial NCT00430261 study?
This clinical trial studies the following conditions: Lung Cancer, Adenocarcinoma.
What interventions are being tested in trial NCT00430261?
The interventions under investigation include: sunitinib (DRUG).
Who is sponsoring clinical trial NCT00430261?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00430261 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00430261's enrollment target sits among peer trials
20 356th of 409 higher than 46 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Novel Treatment Combinations in Patients With Lung Cancer
RECRUITING · Phase 2
-
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®
RECRUITING · Phase 2
-
ATATcH Alternating Treatment Plans for Advanced Cancer
RECRUITING · Phase 2
-
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia